Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $955269 | $943016 | — | — | — | — |
| Enterprise Value | $2M | $2M | — | — | — | — |
| P/E Ratio → | -0.08 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -2.3% | 1.7% |
| ROA | -610.9% | -610.9% | -79.2% | -12.3% | -2.0% | 1.6% |
| ROIC | — | — | — | -22.0% | -1.5% | — |
| ROCE | — | — | — | -46.0% | -1.9% | -0.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 12.75 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | 0.02 |
| Net Debt / Equity | — | — | — | — | 8.85 | -0.00 |
| Net Debt / EBITDA | — | — | — | — | — | -0.06 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -46.27 | -46.27 | -19.89 | -6.22 | -12.37 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.05 | 0.05 | 0.09 | 0.04 | 0.10 | 0.31 |
| Quick Ratio | 0.05 | 0.05 | 0.09 | 0.04 | 0.10 | 0.31 |
| Cash Ratio | 0.03 | 0.03 | 0.09 | 0.08 | 1.41 | 0.24 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $24M | $7M | $8M | $34M | $35M |
Imminent liquidity insolvency risk
As reported in recent financial statements, Liminatus Pharma's current ratio has collapsed to 0.05 by 2025Q4, indicating that the firm lacks the necessary liquid assets to cover its immediate obligations and sustain its ongoing research and development activities without an urgent, dilutive capital infusion.
The rapid decline in the current ratio from 0.96 in 2026Q1 to 0.05 suggests that the company is effectively operating on a day-to-day basis. This extreme liquidity constraint implies that the firm is highly vulnerable to any unexpected clinical or regulatory delays, which would likely necessitate an immediate cessation of operations.
Based on historical data, the company's ROA has consistently remained in negative territory, reaching -112.2% in 2025Q3, which underscores the structural inability of the current business model to generate any meaningful return on the capital invested by shareholders during its pre-revenue clinical development phase.
The persistent negative ROA indicates that the company is consuming its capital base at an accelerating rate without achieving the clinical milestones required to justify such expenditures. This trend suggests that the firm is failing to compound value, as the capital is being deployed into high-risk R&D that has yet to demonstrate any path toward commercial viability.
According to the provided quarterly data, the company's DPO reached an extreme level of 96,603 days in 2026Q1, which suggests that the firm is likely delaying payments to vendors and service providers as a desperate measure to preserve its dwindling cash reserves for essential clinical operations.
This anomalous DPO figure is a strong indicator of severe financial stress rather than operational efficiency. It implies that the company's relationships with suppliers and clinical research organizations may be strained, potentially jeopardizing the progress of its GUCY2C-targeted CAR-T trials due to the inability to meet contractual payment obligations.
Investors frequently misapply traditional P/E and EV/EBITDA multiples to Liminatus Pharma, which, as noted in recent SEC filings, are entirely inappropriate for a pre-revenue entity that lacks the operational scale and consistent cash flows required to make such valuation metrics meaningful for assessing intrinsic value.
Using these multiples obscures the reality that the company's valuation is driven entirely by speculative clinical outcomes rather than current earnings. Analysts should instead focus on 'cash runway' and 'clinical milestone probability' to evaluate the firm, as traditional profitability ratios provide no insight into the company's survival prospects.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LIMNW stock.
Liminatus Pharma, Inc. Warrants's current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Based on historical data, Liminatus Pharma, Inc. Warrants is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.